Altas Doses de VP-16, Ciclofosfamida e Irradiação Corpórea Total Hiperfracionada Seguida de Transplante Alogeneico de Medula óssea: Um Regime Agressivo e Bem Tolerado no Tratamento de Neoplasias Hematológicas de Mau Prognóstico – Resultados Preliminares
DOI:
https://doi.org/10.32635/2176-9745.RBC.1987v33n2.3204Palavras-chave:
Altas Doses Quimioterapia, Transplante de Medula Óssea, Mucosite, LeucemiaResumo
No período de agosto/86 a fevereiro/87, três pacientes foram tratados com VP-16-1800mg/m2, em infusão única em 26 horas no dia -6, seguida por Ciclo fosfamida (EDX) 50mg/kg/d nos dias -4 e -3. Irradiação corpórea total (ICT) 1000 cGy em 5 frações de 200cG y nos dias -2, -1 e 0. O transplante de medula óssea (TMO) foi realizado no dia O utilizando doadores HLA compatíveis. O estudo incluiu três pacientes: um paciente portador de Leucemia Linfoblástica Aguda (LLA) em 1.ª recaída medular; um paciente portador de Leucemia Mielóide Crônica (LMC) em 2.ª fase crônica e um paciente portador de LLA em 2.ª remissão. A idade variou entre quatro e 29 anos. A principal toxicidade apresentada por este regime foi mucosite severa que ocorreu nos três pacientes. Todos os três pacientes apresentaram ulcerações orais e um deles apresentou diarréia hemorrágica com volume superiora dois litros. Em todos os pacientes o quadro se resolveu nas três semanas que se seguiram ao TMO. Um paciente apresentou alterações eletrocardiográficas significativas sem, entretanto, ocorrerem manifestações clínicas de cardiotoxicidade. A eficácia do regime pode ser testada no paciente em recaída que permanece em remissão 210 dias pós-TMO. No paciente portador de LMC houve eliminação do cromossomo Ph1. Concluímos que VP-16/EDX/ICT é um regime eficaz e bem tolerado no tratamento de neoplasias hematológicas.
Downloads
Referências
Weiden PL, Flournoy N, Sanders J, et al - Antileukemie effect of Graft versus Host Disease contributes to improved survival after allogeneic marrow transplantation. Transplant Proc, 1981, 13: 248
Mitsuyasu RT Champlin RE, Gele AR, et al - Treatment of donor bone marrow with monoclonal anti T cell antibody and complement for the prevention of versus Host Disease after marrow transplantatjon for leukemia. Ann int Med, 1986, 105.20. DOI: https://doi.org/10.7326/0003-4819-105-1-20
Badger C, Buckner CD, Thomas ED, et al - Allogeneic marrow transplantation for acute leucemia in relapse Leuk Res, 1982; 6:383. DOI: https://doi.org/10.1016/0145-2126(82)90101-1
Gele RP, Kar HEM, Rim AA, et al - Bone marrow transplantation for acute leukemia in first remission Lancet, 1982; 2: 1006 DOI: https://doi.org/10.1016/S0140-6736(82)90048-4
Gala AR, Kersey JH, Bortin MM, et al - Bone marrow transplantation for acute lymphoblastic leukemia Lancet, 1983; 2663
Thomas ED, Chft RA, Fefer A, et al - Marrow transplantatron for the treatment of chronic myelogenous leukemia. Ann int Med, 1986, 104:155. DOI: https://doi.org/10.7326/0003-4819-104-2-155
Bortin MM, Gale AR - Current status of allogeneic bone marrow transplantation A report from the international Bone Marrow Transplant Registry. Clinical Transplant., 1986. DOI: https://doi.org/10.1016/S0147-0272(86)80011-3
Weiss AR - Hypersensitivity reactions to cancer chemotherapy, Semin Oncol, 1982, 9.5.
Storb A, Deeg HJ, Whitehead ,J, et ai. Methotrexate and Cyclosporine compared with Cyclosporine alone for prophylaxis of acute Graft versus Host Disease after marrow transplantation for leukemia, New Eng J Med, 1986; 314:729 DOI: https://doi.org/10.1056/NEJM198603203141201
Frei E III, Canellos GP - Dose: A critical factor in cencer chemotherapy. Am J Med, 1980; 69:585. DOI: https://doi.org/10.1016/0002-9343(80)90472-6
Steel GG - Growth and survival of tumor stem cells in, Growth Kinetics of Tumors Oxford Clarindon Press, 1977, 244-267.
Thomas ED - The use and potential of bone marrow aiograft and whole body irradiation in the treatment of leukemia. Cancer, 1982; 50: 1449 DOI: https://doi.org/10.1002/1097-0142(19821015)50:8<1449::AID-CNCR2820500802>3.0.CO;2-P
Brochstern iA, Kernan N, Emanuei D, et al - Marrow transplantation for acute leukemia after hyperfractionated total body irradiation and cyclophosphamide Blood, 1986; 68: 271.
Blume KG, Forman Si, O'Donneli MA et al - Total body irradiation and high dose VP-16: An effective preparatory regimen for bone marrow transpiantation of patients with advanced hematological malignancies. Biood, 1985, 66: 249.
Coccia PF, Strandjord SE, Gordon EM, et al - High dose cytosine arabinoside and fractionated total body irradiation: An improved preparative regimen for bone marrow transplantation of chridren with acute lymphoblastic leukemia in second remission. Biood, 1984; 64: 213.
Wiernik G - The significance of the time-dose reiationship in radiotherapy, Br Med Bui, 1973; 29:39, DOI: https://doi.org/10.1093/oxfordjournals.bmb.a070954
Peters Li, Withers HR, Cunoiff JH, Dicke KA - Radiological considerations in the use of total body irradiation for bone marrow transpientatron. Radiology, 1979; 131.243, DOI: https://doi.org/10.1148/131.1.243
Wolff SN, Fer MF, McWay CM, et al - High dose VP-16213 and autologous bone marrow transplantation for refractory meignencres. A phase 1 study. i Clin Onc, 1983; 1701 DOI: https://doi.org/10.1200/JCO.1983.1.11.701
Wozniak Ai, Lrsson BS, Hende KA, Aoss WE -. inhibition of etoposide induced DNA damege and cytotoxicity in L 1210 ceis by dehydrogenase inhibitors and other agents. Cancer Res, 1984; 44:626.
Aoss W, Rowe T, Ghsson 8, Yeiowich J, Lin L - Role of topoisomeras 11 in mediating epidophyiotoxin induced DNA cleevage. Cancer Res, 1984; 445857.
Lee T, Roberts D - Flue of teniposide across lhe plasma membrane of teniposide resisteni sublines of L 1210 cells. Cancer Res, 1984; 442986
Dombernowsky P, Nissen Nl - Combination chemotherapy with 4' - de- methypipodophyilotoxin 9 - I4,6-0-ethilrdenw -D-gencopyranoside VP-16-213 iNSC 1415401, in L 1210 ieukemia, Eur J Cancer, 1976, 12:181 DOI: https://doi.org/10.1016/0014-2964(76)90239-5
Abromowitch M, Surkule iA, Heyes FA, Rivera G - Continuous infusion teniposide iVM-261 e new effective scheduie of administratron in refractory leucemia (AL) and neuroblestoma iNBl. Proc Am Assoc Cancer Res, 1984; 25:162.
Postmus PE, Muider NH, Sieiffer DT, et al High dose etoposide for refractory malignancies: a phase 1 study. Cancer Treat Rep, 1984; 68:1471.
Hoithuis II M, Postmus PE, Vanoort Wi, et al - Pharmacokinetics of high dose etoposide, Euri Cancer Clín Oncol, 1986; 221149.
Barrett Al, Kendre JR, Luces CP, et al - Cycioporine A es prophyiaxrs egarnst Graft versus Host Disease in 36 petrents, Brit Med i, 1982; 285:162. DOI: https://doi.org/10.1136/bmj.285.6336.162
Postmus PE, de Vrres EG E, Devries-Hospers HG, et al -. Ciclophosphamide and VP-15 213 with eutologous bone marrow transpiantation A dose escelation study. Eur i Cancer Clin Oncol, 1984; 20: 777 DOI: https://doi.org/10.1016/0277-5379(84)90216-5
Durrant S, Chipping PM, Palmers S, Gordon-Smith EC - Cyclosporin A, Methylprednisolone and convulsions. Lancet, 1982; 2.829. DOI: https://doi.org/10.1016/S0140-6736(82)92727-1
Stewart Di, Rrchard MT, Hugenhoitz H, et al - Perretratron of VP-16 (etoposide) mio human intracerebral and estracerebral tumors. J Neuro Oncol, 1984; 2:133. DOI: https://doi.org/10.1007/BF00177899
Postmus PE, Haaxma-Aeiche H, Veneken LM, et al - Remissron of brain metestases from smail celi lung cancer after high dose chemotherapy. Ann ml Med, 1984; 101:717, DOI: https://doi.org/10.7326/0003-4819-101-5-717
Goldberg MA, Antro JH, Guirran EC, Rappefort JN - Ciclofosfamide cardiotoxcity: An analyse of dosing asa risk factor. Blood, 1986; 68:1114 DOI: https://doi.org/10.1182/blood.V68.5.1114.1114
Appelbeum FR, Strauchen IA, Graw IR RG, et al - Acute lethal carditis caused by high dose combrnation chemotherapy. Lancet, 1976; 1:58. DOI: https://doi.org/10.1016/S0140-6736(76)90151-3
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
